Like many cancer medicines, KADCYLA is given as an intravenous (IV) infusion in your doctor’s office, at a hospital, or at an infusion center.
For HER2+ metastatic breast cancer, KADCYLA is given once every 3 weeks, until your disease is no longer controlled or your side effects require you to stop treatment.
After each infusion, your healthcare team will take some extra time to watch how you respond to treatment. If side effects occur, they may adjust, delay, or stop your treatment.
If you miss a dose of KADCYLA, DO NOT WAIT until your next 3-week cycle of treatment. Contact your doctor or nurse right away and work with them to reschedule the treatment you missed.
Need help starting the conversation? Get a list of questions to ask your doctor before and during treatment with KADCYLA.
Get information and support for your treatment journey with HERConnection.
The information contained in this section of the site is intended for U.S. healthcare professionals only. Click "OK" if you are a healthcare professional.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.